journal article·2026

Engineering strategies of bacterial outer membrane vesicles for enhancing tumor immunotherapy

Zhengxin Yu, Yichuan Ma, Qi Guo, Huifang Liu, Zhenhua Li, Jinchao Zhang

Nanoscale· Volume 18· Issue 24
Publisher page

Abstract

Outer membrane vesicles (OMVs) have emerged as highly promising bio-derived nanoplatforms in tumor immunotherapy due to their inherent immunogenicity, structural diversity, and molecular customization capabilities. Recent studies have introduced various engineering strategies to enhance their therapeutic efficacy, yet these approaches are often presented as isolated modifications lacking a unified functional theoretical framework. This paper categorizes OMVs engineering techniques into pre-isolation and post-isolation strategies, analyzing how they regulate antigen presentation, immune activation, biodistribution, and therapeutic integration within the tumor immune cycle. By comparing the advantages, limitations, and applicable scenarios of genetic, metabolic, chemical, and physical modifications, we propose a function-oriented design framework. Simultaneously, we address critical challenges including safety control, production consistency, and mechanism standardization, charting future pathways for translating engineered OMVs into clinically viable cancer immunotherapies.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bacterial Infections and Vaccines · Nanoplatforms for cancer theranostics · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Chemistry & Materials Science, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding 071002, China

College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China

The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hebei Province

References (67)

Show source-provided references
1. Jeong · Acta Biomater. · 2024 · 178 · 1310.1016/j.actbio.2024.02.029 ↗
2. Tian · Vet. Microbiol. · 2024 · 294 · 11013110.1016/j.vetmic.2024.110131 ↗
3. Yang · Immunity · 2019 · 50 · 69210.1016/j.immuni.2019.02.001 ↗
4. Effah · Front. Immunol. · 2024 · 15 · 129606110.3389/fimmu.2024.1296061 ↗
5. Wei · J. Cell. Physiol. · 2019 · 235 · 484310.1002/jcp.29362 ↗
6. Xie · Trends Biotechnol. · 2022 · 40 · 117310.1016/j.tibtech.2022.03.005 ↗
7. Han · ACS Nano · 2023 · 17 · 1871610.1021/acsnano.3c01912 ↗
8. Xiao · Bioact. Mater. · 2024 · 36 · 48
9. Luo · Adv. Sci. · 2024 · 11 · 240004910.1002/advs.202400049 ↗
10. Cheng · Nat. Commun. · 2021 · 12 · 204110.1038/s41467-021-22308-8 ↗
11. Shen · Nature · 2023 · 617 · 18510.1038/s41586-023-05988-8 ↗
12. Li · Adv. Mater. · 2022 · 34 · 210998410.1002/adma.202109984 ↗
13. Li · Adv. Funct. Mater. · 2024 · 34 · 240135510.1002/adfm.202401355 ↗
14. Li · ACS Nano · 2020 · 14 · 1669810.1021/acsnano.0c03776 ↗
15. Gujrati · ACS Nano · 2014 · 8 · 152510.1021/nn405724x ↗
16. You · Adv. Mater. · 2025 · 37 · 241805310.1002/adma.202418053 ↗
17. Shen · J. Extracell. Vesicles · 2025 · 14 · e7020710.1002/jev2.70207 ↗
18. Micoli · BioDrugs · 2023 · 38 · 4710.1007/s40259-023-00627-0 ↗
19. Qiao · Front. Microbiol. · 2021 · 12 · 72936910.3389/fmicb.2021.729369 ↗
20. Modification of Lipid A Biosynthesis inNeisseria meningitidis lpxL Mutants: Influence on Lipopolysaccharide Structure, Toxicity, and Adjuvant Activity
21. Meng · J. Extracell. Vesicles · 2022 · 11 · e1228910.1002/jev2.12289 ↗
22. Richter · Adv. Drug Delivery Rev. · 2021 · 173 · 41610.1016/j.addr.2021.03.020 ↗
23. Feng · Adv. Mater. · 2022 · 34 · 220620010.1002/adma.202206200 ↗
24. Li · Nano Res. · 2023 · 17 · 83610.1007/s12274-023-6225-6 ↗
25. Li · Anal. Chem. · 2024 · 96 · 1958510.1021/acs.analchem.4c04449 ↗
26. Qing · Adv. Mater. · 2020 · 32 · 200208510.1002/adma.202002085 ↗
27. Chen · ACS Nano · 2024 · 18 · 135710.1021/acsnano.3c05714 ↗
28. Sun · J. Nanobiotechnol. · 2024 · 22 · 47410.1186/s12951-024-02747-3 ↗
29. Chen · ACS Nano · 2023 · 17 · 773310.1021/acsnano.3c00363 ↗
30. Long · Adv. Drug Delivery Rev. · 2022 · 186 · 11432110.1016/j.addr.2022.114321 ↗
31. Ban · Nat. Commun. · 2023 · 14 · 293310.1038/s41467-023-38679-z ↗
32. Sun · J. Controlled Release · 2026 · 390 · 11451410.1016/j.jconrel.2025.114514 ↗
33. Wang · Nat. Commun. · 2024 · 15 · 366910.1038/s41467-024-48032-7 ↗
34. Li · Nat. Biomed. Eng. · 2026 · 10 · 66010.1038/s41551-025-01575-6 ↗
35. Lu · Adv. Mater. · 2025 · 37 · 241339210.1002/adma.202413392 ↗
36. Sun · ACS Nano · 2024 · 18 · 3529610.1021/acsnano.4c11412 ↗
37. Zou · Nano Lett. · 2021 · 21 · 860910.1021/acs.nanolett.1c02482 ↗
38. Luo · Nano Res. · 2024 · 17 · 838910.1007/s12274-024-6861-5 ↗
39. Zhuang · Nano Lett. · 2022 · 22 · 449110.1021/acs.nanolett.2c01280 ↗
40. Khleif · Nat. Immunol. · 2025 · 26 · 187710.1038/s41590-025-02308-2 ↗
41. Wang · Adv. Mater. · 2025 · 37 · 250156510.1002/adma.202501565 ↗
42. Chen · J. Nanobiotechnol. · 2025 · 23 · 51410.1186/s12951-025-03507-7 ↗
43. Liang · Drug Des. Devel. Ther. · 2024 · 18 · 183310.2147/DDDT.S457338 ↗
44. Lin · ACS Nano · 2025 · 19 · 1986610.1021/acsnano.5c02541 ↗
45. Xiang · J. Pharm. Anal. · 2024 · 14 · 10104910.1016/j.jpha.2024.101049 ↗
46. Hamza · Acta Pharm. Sin. B · 2025 · 15 · 264010.1016/j.apsb.2025.03.014 ↗
47. Leitner · Infect. Immun. · 2013 · 81 · 237910.1128/IAI.01382-12 ↗
48. Chen · ACS Synth. Biol. · 2025 · 14 · 14810.1021/acssynbio.4c00483 ↗
49. Lu · Vaccines · 2025 · 13 · 55210.3390/vaccines13060552 ↗
50. Yue · Nat. Biomed. Eng. · 2022 · 6 · 89810.1038/s41551-022-00886-2 ↗
51. Wang · J. Transl. Med. · 2024 · 22 · 37810.1186/s12967-024-05195-7 ↗
52. Luo · Adv. Sci. · 2024 · 11 · 240004910.1002/advs.202400049 ↗
53. Barbero · Semin. Immunol. · 2017 · 34 · 5210.1016/j.smim.2017.10.001 ↗
54. Zhao · Microb. Cell Fact. · 2025 · 24 · 2710.1186/s12934-025-02653-9 ↗
55. Sonallya · J. Colloid Interface Sci. · 2025 · 679 · 49610.1016/j.jcis.2024.09.244 ↗
56. Belyaev · Adv. Drug Delivery Rev. · 2025 · 219 · 11555010.1016/j.addr.2025.115550 ↗
57. Mayordomo · Biomimetics · 2025 · 10 · 27610.3390/biomimetics10050276 ↗
58. Deng · Int. J. Nanomed. · 2025 · 20 · 657310.2147/IJN.S513508 ↗
59. de Vlieger · AAPS J. · 2019 · 21 · 5610.1208/s12248-019-0329-7 ↗
60. Rodríguez-Gómez · Front. Med. · 2025 · 12 · 154439310.3389/fmed.2025.1544393 ↗
61. Zhang · Front. Immunol. · 2026 · 17 · 170739110.3389/fimmu.2026.1707391 ↗
62. EMA , Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials , 2025
63. USP General Chapter BACTERIAL ENDOTOXINS TEST
64. Giannelli · AAPS J. · 2024 · 26 · 3210.1208/s12248-024-00902-0 ↗
65. Micoli · BioDrugs · 2023 · 38 · 4710.1007/s40259-023-00627-0 ↗
66. Kim · Nat. Commun. · 2017 · 8 · 62610.1038/s41467-017-00729-8 ↗
67. Micoli · BioDrugs · 2023 · 38 · 4710.1007/s40259-023-00627-0 ↗